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AUTOANTIBODY PROFILES IN SYSTEMIC LUPUS ERYTHEMATOSUS 
SUPPORT A GLOBAL DEFECT IN IMMUNE TOLERANCE. Ingrid H. 
Olhoffer and Joseph Craft. Section of Rheumatology, Department of 
Internal Medicine, Yale University, School of Medicine, New Haven, CT. 
Systemic lupus erythematosus (SLE) is manifested by a diversity of both 
clinical manifestations and autoantibody specificities. Previous studies 
have suggested that autoantibody specificities in SLE occur in pairs (dsDNA 
and histone, Ro and La, Sm and U1 ribonucleoprotein). This led to the 
hypothesis that the autoimmune response in lupus targets particles - the 
nucleosome, the Ro/La ribonucleoprotein particle, and/or the spliceosome. 
Given this theory, we studied the frequency of autoantibody sets and the 
average number of autoantibody sets per SLE patient in regard to the 
etiology of lupus. Sera of sixty-eight patients fulfilling the American 
Rheumatology Association 1982 Revised Criteria for SLE were studied for 
autoantibody sets by 35S immunoprecipitation and ELISA analysis, and 
autoantibody profiles previously reported in the literature were examined 
for the prevalence of autoantibody sets and the average number of 
autoantibody sets per patient. Clinical/autoantibody associations, in this 
previously unreported population, were determined using Chi-square 
analysis with Yates' correction. The prevalences of autoantibody sets of the 
following specificities were as follows: dsDNA and/or histone (59%), Sm 
and/or U1 RNP (40%), and Ro and/or La (41%). The current study and 
twelve identified studies in the literature showed an average of two or 
greater autoantibody sets per patient supporting lupus etiologic theories 
consistent with a global defect in immune tolerance. The following 
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associations, which are consistent with the literature, were found - anti- 
dsDNA antibodies correlated with renal pathology; anti-dsDNA and anti¬ 
histone antibodies correlated with hypocomplementemia; and anti-La 
antibodies correlated with Rheumatoid Factor. 

ABBREVIATIONS 
ANA Antinuclear antibody 
ARA American Rheumatology Association 
BSA Bovine serum albumin 
CIE Counterimmunoelectrophoresis 
DNA Deoxyribonucleic acid 
ds Double-stranded 
EDTA Ethylenediamine-tetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 





MCTD Mixed connective tissue disease 
MHC Major histocompatibility complex 
MRL Murphy's recombinant large 
mRNA Messenger ribonucleic acid 
MW Molecular weight 
nRNP Nuclear ribonucleoprotein 
NZB New Zealand Black 
NZW New Zealand White 
PBCA Polyclonal B cell activation 
PCNA Proliferating cell nuclear antigen 
PTCA Polyclonal T cell activation 
RF Rheumatoid factor 

RNA Ribonucleic acid 
RNP Ribonucleoprotein 
rRNA Ribosomal ribonucleic acid 
SCLE Subacute cutaneous lupus erythematosus 
scRNP Small cytoplasmic ribonucleoprotein 
SD Standard difference 
SDS Sodium dodecyl sulfate 
SLE Systemic lupus erythematosus 
Sm Smith 
snRNP Small nuclear ribonucleoprotein 
ss Single-stranded 
SS Sjogren's syndrome 
Th Helper T cell 




Systemic lupus erythematosus (SLE) is manifested by a diversity of 
both clinical manifestations and autoantibody specificities. Clinical 
manifestations include: dermatologic disease, serositis, musculoskeletal 
disease, neurological disease, vascular disease, renal pathology, 
hematologic disease, and constitutional symptoms (Tan et al., 1982). 
Autoantibodies in SLE can be artificially divided into organ specific versus 
organ non-specific antibodies (Tan 1993). The organ specific antibodies are 
directed against antigens present in only a subset of cells, for example, the 
hematopoietic cellular elements (red cells, white cells, and platelets) (Tan 
1993); whereas organ non-specific antibodies (the focus of this project) are 
directed against subcellular nuclear and cytoplasmic antigens common to 
virtually every cell type, including double-stranded (ds) DNA, histones, Sm, 
U1 ribonucleoprotein (RNP), Ro, La, ribosomal proteins, proliferating cell 
nuclear antigen (PCNA), Ku, and Ki (Boey et al., 1988). These 
autoantibodies have been used as markers to confirm diagnosis, shown to 
play a direct role in the pathogenesis of disease, correlated with clinical 
manifestations, used as tools for the structural analysis of the 
autoantigens, and examined for clues to the etiology of lupus. Possible 
etiologies include: modification of self determinants, molecular mimicry, 
polyclonal B cell activation (PBCA), polyclonal T cell activation (PTCA), 
disclosure of "privileged sites," disclosure of "cryptic self," activation of 
ignorant autoreactive cells, a deficit in T and/or B cell tolerance, or an 
immunoregulatory disturbance (Theofilopoulos 1995). The present study 
takes a novel approach to examining autoantibody profiles for clues to the 
etiology of SLE. In order to address this question, the following introduction 
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will briefly detail the history of the autoantibodies, the molecular biology of 
the autoantigens, the methods for detection of autoantibodies, the clinical 
associations of the autoantibodies, and the various theories regarding the 
genesis of autoantibodies. 
History of Autoantibodies in SLE 
Serological markers of the connective tissue diseases have an 
extended history of being studied. In 1948, Hargraves, one of the pioneers 
in laboratory rheumatology, described the phenomenon of the LE (lupus 
erythematosus) cell in bone marrow and associated it with SLE (Hargraves 
et al., 1948). Shortly thereafter, Kunkel and colleagues showed that the LE 
phenomenon was secondary to circulating antibodies against DNA, cell 
nuclei and deoxyribonucleoprotein (which direct phagocytosis by 
polymorphonuclear leukocytes), giving new insight into the 
immunopathogenesis of SLE and shaping the development of modern 
concepts of autoimmunity (reviewed in Tan 1989; and Christian and Elkon, 
1986). 
Since these early studies led the way for other investigators, many 
other autoantibodies have been identified. In 1959, antibodies to DNA were 
first reported (reviewed in Tan 1993). In 1961, Kunkel et al. described anti¬ 
histone antibodies (reviewed in Christian and Elkon, 1986). Discovery of the 
small nuclear ribonucleoprotein (snRNP) particles began in the early 1960s 
with anti-Sm being first described in SLE patients in 1966 by Tan and 
Kunkel and nRNP (now called U1 RNP) being described in 1971 (reviewed in 
Hardin 1989, and Mattioli and Reichlin, 1971). Antibodies to ribosomes 
were first described in 1963 (reviewed in Bonfa and Elkon, 1986). Anti-Ro 
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and anti-La antibodies were first reported to occur in patients with SLE in 
1968 (reviewed in Reichlin, 1985), and in 1979, an interlaboratory 
collaboration showed these antigens to be equal to the SS-A and SS-B 
antigens, respectively (SS-A and SS-B were originally described in Sjogren's 
syndrome) (Alspaugh and Maddison, 1979). An “autoantibody to a nuclear 
antigen in proliferating cells” (PCNA) was first reported in 1978 (Miyachi et 
al., 1978). 
Discoveries continued into the 1980s. Anti-Ku antibodies, which were 
first isolated in patients with polymyositis-scleroderma overlap syndrome, 
were isolated in SLE patients in 1981 (reviewed in Reeves 1985). Also in 
1981, Tono et al. found that SLE patients have antibodies which target the Ki 
antigen (reviewed in Sakamoto et al., 1989). The SL antigen, first reported 
by Harmon et al. in 1981, has since been shown to be equivalent to Ki 
(Bernstein et al., 1986; Sakamoto et al., 1989). 
Also of historical importance, many autoantibody specificities were 
discovered using patient sera and were therefore originally named after the 
patient in whom they were first described (Christian and Elkon, 1986). For 
example, anti-Sm and anti-Ku antibodies were first described in the sera of 
patients Smith and Ku (Craft and Hardin, 1992; Christian and Elkon, 1986). 
Characteristics of Autoantigens in SLE 
Using patient autoantibodies as probes together with recent advances 
in molecular biology, investigators have accumulated a considerable 
amount of knowledge regarding the molecular identity and biological 
functions of the autoantigens targeted in lupus (Table 1). 
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DNA Many patients with SLE have sera specific for their genetic 
material, deoxyribonucleic acid (DNA). DNA is a polymer of 
deoxyribonucleotides whose function can be described as "the storehouse of 
information specifying all facets of the cell's existence (Geis 1983)". Much 
research has described the antigenic determinants recognized by anti-DNA 
antibodies. Antibodies to dsDNA react with antigenic determinants present 
on both double and single-stranded (ss) DNA (mainly the deoxyribose 
phosphate backbone) (reviewed in Tan 1993), whereas, antibodies to ssDNA 
target the purine and pyrimidine bases exposed in ssDNA (reviewed in Tan 
1989 and Tan 1993). 
Histones Histones are a highly conserved family of basic proteins within 
the nucleus which together with DNA make up nucleosomes. 
Nucleosomes are highly structured units consisting of H2A-H2B dimers 
and H3-H4 tetramers forming a core structure around which helices of 
dsDNA are wound (reviewed in Tan 1989). HI proteins mediate a higher 
order of packing (reviewed in Craft and Hardin, 1992). In SLE, 
autoantibodies to histones are targeted at all the classes of histones, HI, 
H2A, H2B, H3, H4, as well as the H2A/H2B and H3/H4 complexes (reviewed 
in Tan 1989 and Tan 1993). 
snRNP Antigens In 1979, Lerner and Steitz first elucidated the structure 
and function of these antigens which are classified as small nuclear 
ribonucleoprotein (snRNP) particles - Ul, U2, and U4-U6. Structurally, 
each spliceosome snRNP particle consists of the corresponding U (uridine 
rich) small RNA (Ul, U2, U4, U5, or U6), distinct from tRNA, mRNA and 
rRNA, and associated polypeptides. The Sm protein complex consists of 
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six polypeptides B (28 kD), B’ (29 kD), D (16 kD), and E-G (13-11 kD) which 
are common to the Ul, U2, and U4-U6 snRNPs; whereas, the 70K (70 kD), 
A (33 kD), and C (22 kD) polypeptides are uniquely associated with the Ul 
snRNP. (reviewed in Tan 1989; and Craft et al., 1988; and Hardin 1986) 
Functionally, snRNP particles are involved in splicing pre-mRNA as 
a part of the spliceosome machinery located in the nucleus. The proteins of 
these particles have most commonly been shown to be the immune target; 
however, antibodies to the RNA component have also been identified 
(Wilusz and Keene, 1986). Specifically, anti-Ul RNP antibodies bind 70K, A, 
and/or C; anti-Sm antibodies bind B, B', D and/or E recognizing one or more 
epitopes (they may also bind F and/or G) (reviewed in Tan 1989); and anti- 
U2 RNP antibodies bind A’ and B” (Craft et al., 1988). E, F and G are rarely 
autoimmune targets (reviewed in Tan 1989, and Hardin 1989). 
Other important aspects of the snRNP binding specificities have been 
elucidated. For example, there is a shared conformational epitope on BVB 
and D recognized by a monoclonal antibody called Y12. Furthermore, it has 
been noted that several epitopes are common to the various peptides and 
they have therefore been suggested as “pivotal” in the SLE autoimmune 
response, (reviewed in Hardin 1989) 
Ro Anti-Ro/SS-A positive sera bind ribonucleoprotein particles. Each 
particle consists of probably two Ro proteins (52 kD and 60 kD) and 4-5 small 
RNAs called Y RNAs (reviewed in Tan 1989; and Craft and Hardin, 1992). 
The Ro RNAs are transcribed by RNA polymerase III. Initially thought to 
be cytoplasmic, Ro antigen is now believed to be nuclear in origin (Clark et 
al., 1969). The function of Ro is unknown. 
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La La/SS-B is a conserved phosphoprotein of 46 to 48 kD. Gottlieb and Steitz 
in 1989, suggested that La is a RNA polymerase III termination factor 
(Gottlieb and Steitz, 1989). Interestingly, anti-La antibodies have been 
shown to target an antigen present on both the Ro and La particles, 
(reviewed in Tan 1989) 
Ribosomal P Proteins Antibodies to ribosomal ribonucleoprotein (rRNP) 
are directed against three proteins, PO, PI, and P2 (of 38 kD, 16 kD, and 15 
kD, respectively) of the 60S ribosomal subunit (Elkon et al., 1988). As a part 
of the translation machinery, these proteins are at least indirectly involved 
in mRNA translation and protein synthesis. Accordingly, on ANA 
immunofluorescence, staining for these proteins is seen in both the 
nucleolus and cytoplasm (reviewed in Craft and Hardin, 1992). 
Ku Ku, also called p70/p8Q, is represented by a doublet of proteins of 60-66 
kD and 81-86 kD (reviewed in Tan 1989; Sakamoto et al., 1989). At least 
three epitopes (one common to both proteins) have been identified 
(Francoeur et al 1986). Ku is the regulatory component of a DNA-dependent 
protein kinase (Dvir et al., 1992, Gottlieb and Jackson, 1993). 
Ki Ki is a nuclear protein of 32 kD whose function is unknown (Sakamoto 
et al., 1989). 
PCNA As a 36 kD cell cycle-regulated proliferation-associated protein, 
PCNA is used as a probe for identifying proliferating cells and has been 
reported to be the auxiliary protein of DNA polymerase-delta (Miyachi et al., 
1978; reviewed in Craft and Hardin, 1992; Swaak et al., 1990). 
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Detection of Autoantibodies 
Many techniques have been used to study the serology of SLE 
including: tissue section immunofluorescence, cell substrate 
immunofluorescence, Farr radioimmunoassay, Crithidia immunoassay, 
immunodiffusion, counterimmunoelectrophoresis, ELISA, western 
blotting, and immunoprecipitation. Throughout the years, many 
seemingly conflicting studies of SLE autoantibodies have used different 
assays. Accordingly, much of the discordant data in the literature may be 
explained by differences in assay sensitivities and specificities. 
ANA Immunofluorescence Antinuclear antibody immunofluorescence is 
the most prevalent screening assay for the detection and quantification of 
ANAs. Tissue section immunofluorescence and cell substrate 
immunofluorescence are sensitive, nonspecific screens for autoantibodies 
which are usually followed by more specific antibody tests (Christian and 
Elkon, 1986). 
Anti-dsDNA Detection The common techniques for anti-dsDNA detection 
include the Farr radioimmunoassay, the Crithidia immunofluorescence 
assay, and the ELISA (Christian and Elkon, 1986). The Farr assay, 
described in 1968, is based on separating free DNA from DNA-antibody 
complexes using saturated ammonium sulfate solutions (Wold et al., 1968). 
The Crithidia assay uses a stage double-stranded solid phase form of DNA 
for semiautomated immunofluorescent intensity quantification (Christian 
and Elkon, 1986). ELISAs (enzyme-linked immunosorbent assays) involve 
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using purified antigen as bound substrate which is then probed with 
unknown sera, with bound antibodies being detected with labeled anti-IgG 
antibodies. Studies comparing various assays have found varying 
sensitivities and specificities (reviewed in Craft and Hardin, 1992). In a 
study by Swaak et al., sensitivities and specificities varied depending on the 
clinical manifestations of the SLE patient population. In particular, Swaak 
et al. showed qualitative and quantitative differences between patients with 
CNS lupus manifestations and nephritis (Swaak et al., 1990). 
Immunodiffusion Sm, U1 RNP, Ro and La antisera were originally 
detected by immunodiffusion analysis, according to Ouchterlony. In this 
assay, the presence of autoantibodies results in the formation of a visible 
precipitin line between antigen of various mammalian tissue extracts and 
specific antibody (reviewed in Craft and Hardin, 1992; and Tan 1991). This 
technique, which has also been used to detect anti-PCNA (Boey et al., 1988) 
and anti-Ku antibodies, is dependent on antigen solubility (detecting only 
precipitating antibodies), antigen abundance, and protein half-life 
(reviewed in Christian and Elkon, 1986; and Tan 1991). Specifically, Sm, 
U1 RNP, and La tend to be highly abundant and soluble in most 
mammalian tissue, whereas Ro is present in lower concentrations in 
species such as rats or mice (reviewed in Christian and Elkon, 1986). 
Because the Ro antigen varies in concentration in cells from one animal 
species to the next, many traditionally “ANA-negative” lupus patients have 
anti-Ro (reviewed in Christian and Elkon, 1986). A newer technique related 
to immunodiffusion is counterimmunoelectrophoresis (CIE) (reviewed in 
Christian and Elkon, 1986). 
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ELISA Described above, ELISAs are currently used both in research and 
clinically to screen for specific autoantigens. Numerous studies have been 
done comparing various detection assays with ELISAs. Maddison et al. 
showed that ELISA has a greater sensitivity but lower specificity in 
comparison with immunodiffusion for nRNP, Sm, Ro and La (Maddison et 
al., 1985). Anti-histone antibodies are usually detected with ELISA because 
histones are insoluble at physiologic ionic strength and pH. (reviewed in 
Christian and Elkon, 1986) 
lmmunoprecipitation (IPP) (See methods section for description of 
technique.) Currently one of the most sensitive and specific methods for 
characterizing the targets of autoantibodies is immunoprecipitation 
(reviewed in Craft and Hardin, 1992; and Christian and Elkon, 1986). 
Kessler was one of the first to use the technique of immunoprecipitation 
(reviewed in Christian and Elkon, 1986), and in 1979, Lerner and Steitz 
used this technique to immunoprecipitate radiolabeled RNA protein 
complexes (Lerner and Steitz, 1981). Immunoprecipitation to detect anti- 
snRNP, anti-Ro, and anti-La antibodies is well described (Craft and 
Hardin, 1992). Immunoprecipitation has also been used to identify 
antibodies to rRNP, Ki and Ku (Boey et al., 1988). One of the important 
elements of this technique is that non-antigenic proteins and RNA 
associated with the targeted antigen are co-precipitated. 
Immunoprecipitation also has utility in detecting previously unrecognized 
antigens. 
Western Blotting Western blotting involves probing protein which has 
been transferred to nitrocellulose paper after SDS gel separation. It is a very 
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specific way of identifying protein antigens (reviewed in Christian and 
Elkon, 1986). Bonfa and Elkon showed that Western blotting was the most 
sensitive and specific method for the detection of anti-ribosomal P protein 
antibodies in comparison to CIE and cytoplasmic indirect 
immunofluorescence (Bonfa and Elkon, 1986). 
Prevalence of Autoantibodies in SLE 
Frequencies of Individual Autoantibody Specificities The frequency of 
particular autoantibodies found in a given SLE population is assay 
dependent; accordingly, many varying percentages have been reported 
(Table 8). Nevertheless, some generally accepted frequencies are quoted in 
the literature (Table 1). Studies have shown that approximately 40% of SLE 
patients have anti-dsDNA antibodies, and a considerably higher 
percentage, approximately 70%, have anti-ssDNA antibodies (reviewed in 
Tan 1989). Approximately 70% of SLE patients have been shown to have 
anti-histone antibodies (reviewed in Tan 1989). Anti-Sm and anti-Ul RNP 
antibodies are found in approximately 15-30% and 32% of SLE patients, 
respectively (Boey et al., 1988; reviewed in Tan 1989; Swaak et al., 1990). 
Anti-Ro antibodies are present in approximately 35% of SLE patients and 
anti-La antibodies are found in approximately 15% of patients (reviewed in 
Tan 1989). At least 10-15% of patients with SLE have antibodies reactive 
with the ribosomal P proteins (Christian and Elkon, 1986; Elkon et al., 
1988). Anti-Ku antibodies occur in approximately 5-10% of SLE patient sera 
(Boey et al., 1988; reviewed in Tan 1989; Sakamoto et al., 1989), and 6-21% of 
SLE patients have antibodies directed against the 32 kD Ki/SL antigen (Boey 
et al., 1988; Bernstein et al., 1984; Reichlin 1985; Swaak et al., 1990). Anti- 
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PCNA antibodies are present in 3-21.4% of SLE patients (Boey et al., 1988; 
Sakamoto et al., 1989; Swaak et al., 1990). 
Autoantibodies as Markers Autoantibody profiles are important clinically 
in distinguishing SLE from many of the other autoimmune diseases, such 
as, scleroderma, Sjogren's syndrome (SS), mixed connective tissue disease 
(MCTD), and dermatomyositis/polymyositis. Certain antibodies, including 
anti-Sm and anti-dsDNA antibodies, have been shown to be specific 
diagnostic markers for SLE , whereas others, such as anti-ssDNA and anti- 
Ro antibodies, are only minimally helpful in narrowing the differential 
diagnosis. 
Anti-Sm antibodies are generally considered pathognomonic for SLE 
(Notman et al., 1975) and are part of the American Rheumatology 
Association (ARA) 1982 revised criteria (Tan et al., 1982). Furthermore, a 
high titer of antibodies to dsDNA is considered a marker for SLE and is 
rarely present in other diseases (reviewed in Tan 1993; and Craft and 
Hardin, 1992). Whereas the sensitivity of anti-Sm antibodies is only 
approximately 30% for SLE, the majority of patients with active lupus have 
anti-dsDNA reactivity with moderate to high titers (Christian and Elkon, 
1986). Anti-P antibodies have also been reported as fairly specific to SLE. 
Bonfa and Elkon found anti-P antibodies in 17 out of 20 (85%) SLE patients 
versus 0 out of 34 non-SLE patients (Bonfa and Elkon, 1986). 
The other major antibody specificities of SLE are not commonly 
reported as being as specific for SLE. For example, anti-Ul RNP antibodies 
are also found in (and actually necessary for a diagnosis of) MCTD 
(reviewed in Tan 1989; and Craft and Hardin, 1992; and Craft et al., 1988) 
and, rarely, in rheumatoid arthritis, Sjogren's syndrome, scleroderma, 
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and polymyositis (reviewed in Craft and Hardin, 1992). Anti-U2 RNP 
antibodies have been described in patients with MCTD, psoriasis, 
scleroderma-polymyositis overlap syndrome, other overlap syndromes often 
including myositis, and patients without an identified disease (reviewed in 
Craft et al., 1988). Anti-histone antibodies are found additionally in juvenile 
rheumatoid arthritis, rheumatoid arthritis, and in high titer are 
characteristic of patients with drug-induced lupus (reviewed in Craft and 
Hardin, 1992). Anti-ssDNA is present in patients with other rheumatic 
diseases and in patients with nonrheumatic diseases, most commonly 
chronic infection (reviewed in Tan 1993). 
In addition to SLE, anti-Ro and anti-La autoantibodies are found in 
the majority (approximately 70% and 45-60%, respectively) of patients with 
Sjogren's syndrome (reviewed in Tan 1993; Maddison et al., 1985). Ro and 
La specificities are also associated with polymyositis, scleroderma and 
rheumatoid arthritis (reviewed in Craft and Hardin, 1992). Anti-La 
antibodies are also detected in patients with primary biliary cirrhosis and 
patients without a clinical diagnosis (reviewed in Craft and Hardin, 1992). 
Anti-Ku antibodies are seen in patients with scleroderma and MCTD 
(Reeves 1985), and anti-Ki antibodies are found in patients with MCTD, 
primary Sjogren's syndrome, and rheumatoid arthritis, in addition to SLE 
(Sakamoto et al., 1989). 
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Autoantibodies as Monitors of Disease Activity 
Autoantibodies have also been used to monitor disease activity. It has 
most clearly been shown that the titer of anti-dsDNA antibodies can 
correlate with SLE disease activity. Swaak, Tan, and others have noted a 
decrease in anti-dsDNA antibodies that correlates with clinical disease 
exacerbations, compatible with immune-complex formation (reviewed in 
Christian and Elkon, 1986). Other patients with active SLE have been noted 
to have titers magnitudes higher than normal controls and patients with 
inactive SLE (reviewed in Christian and Elkon, 1986). In a study of patients 
with connective tissue diseases, Houtman et al. correlated anti-nRNP/Sm 
levels with disease activity (Houtman et al., 1985). Boey and Tan studied 94 
SLE patients and found that patients with anti-Sm antibodies were more 
likely to have active lupus (Boey et al., 1988). Scopelitis et al., in a small 
study, suggested that anti-Ro titers also correlate with disease activity 
(Scopelitis et al., 1980). Given that autoantibody titers fluctuate, some 
studies of SLE autoantibody profiles have used disease activity as a selection 
criterion including only those sera of patients with a disease exacerbation 
(Swaak et al., 1990). 
Role of Autoantibodies in the Pathogenesis of Disease 
In addition to their role as markers of disease and disease activity, 
autoantibodies in SLE have been shown to play a direct role in tissue 
damage. There is compelling evidence that dsDNA-antibody complexes are 
involved in the pathogenesis of renal disease in many SLE patients by 
mediating immune complex injury (Maddison et al., 1985) and can be a risk 
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factor for nephritis (reviewed in Craft and Hardin, 1992). Glomerular 
eluants have been shown to have more than thousand-fold concentrations of 
anti-dsDNA relative to the sera of the same patient (Christian and Elkon, 
1986). Additionally, ssDNA is present in immune complexes in the 
glomeruli of patients with SLE (Maddison et al., 1985). Further studies have 
shown that the ability of anti-dsDNA antibodies to fix complement 
determines the pathogenicity (reviewed in Craft and Hardin, 1992). 
Evidence exists that implies that anti-Ro antibodies may be directly 
involved in the pathogenesis of neonatal SLE, correlating with both an 
increased risk of neonatal skin rash and congenital complete heart block 
(Maddison et al., 1985). Interestingly, neonatal lupus is characterized by 
anti-Ro and anti-La antibodies in both the mother and the child, with the 
neonatal skin lesions disappearing together with the antibodies which were 
transferred transplacentally (Reichlin, 1985). Anti-Ro antibodies cause 
neonatal heart block by directly affecting the conduction system (Buyon 
1992). In patients with subacute cutaneous lupus erythematosus (SCLE), 
studies have suggested that anti-Ro antibodies may bind to the Ro antigen 
on keratinocytes, contributing to the skin pathology characteristic of this 
disease (reviewed in Craft and Hardin, 1992). Human keratinocytes bind 
anti-Ro and anti-La antibodies if cultured in the presence of estradiol, and 
UV light has been shown to induce anti-Ro antibody binding to 
keratinocytes (reviewed in Tsokos 1992). 
Correlation of Autoantibodies with Clinical Manifestations 
In addition to these studies showing a direct pathologic role for 
antibodies, many past studies have examined the clinical significance of 
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autoantibody profiles in SLE patients by searching for associations between 
autoantibodies and clinical manifestations. Many investigators have 
studied a single antibody and tried to relate it to special clinical features. 
Others have realized that a particular autoantibody specificity does not 
stand alone and have tried relating antibody patterns to clinical features. 
Furthermore, certain antibodies and/or antibody combinations have often 
been proposed to be markers for particular subsets of patients. Associations 
previously reported in the literature are discussed below and shown in 
Table 2. Unfortunately, many reported associations do not duplicate when 
tested by other investigators on different populations and/or with different 
assays. 
dsDNA One of the most widely recognized associations is that of anti- 
dsDNA, hypocomplementemia, and nephritis (reviewed in Tan 1989; and 
Craft and Hardin, 1992; Swaak et al., 1990). Swaak and colleagues looked at 
autoantibody profiles in a group of SLE patients in the Netherlands and 
found that in addition to anti-dsDNA antibodies correlating positively with 
nephritis, they correlate negatively with CNS manifestations (Swaak et al., 
1990); and Thompson et al., in 1993, found an association between anti- 
dsDNA antibodies and hematologic disease and/or a malar rash (however 
these are not widely observed associations). 
Histone In SLE patients, one study associated anti-histone antibodies with 
photosensitivity (reviewed in Tan 1989; and Swaak et al., 1990). More widely 
accepted, anti-histone antibodies, in the absence of anti-dsDNA, anti-Sm 
and other autoantibodies, are characteristic of drug-induced lupus. 
Interestingly, the pattern of anti-histone specificity varies depending if they 
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are drug-induced and if so, which drug caused the antibody response 
(Christian and Elkon, 1986). For example, procainamide-induced anti¬ 
histone antibodies are targeted to the H2A/H2B complex, whereas, 
hydralazine-induced anti-histone antibodies are IgM antibodies targeted 
against histones H3 and H2A (Christian and Elkon, 1986). 
Ro and/or La Maddison and Reichlin, and others, have associated anti-Ro 
antibodies with severe photosensitive dermatitis. (As mentioned above, 
anti-Ro antibodies are believed to have a direct pathological affect on 
keratinocytes.) Some of these dermatitis patients have been classified into a 
subset of lupus designated subacute cutaneous lupus erythematosus 
(SCLE). Patients with subacute cutaneous lupus are highly photosensitive 
and have prominent skin lesions, characterized as a nonscarring 
dermatitis, in the setting of less other organ involvement, (reviewed in 
Maddison et al., 1985) 
Maddison and Reichlin associated anti-Ro positive, anti-La negative, 
sera with lupus nephritis (Maddison et al., 1985). However, in this 
particular study 77% of patients positive only for anti-Ro antibodies also had 
anti-dsDNA antibodies which, as stated above, are generally agreed to be 
involved in the pathogenesis of renal disease in lupus (Maddison et al., 
1985). In a retrospective study of SLE patients by Maddison et al. (reviewed 
in Reichlin 1985), anti-Ro antibodies were also associated with an increased 
frequency of rheumatoid factor positivity (Bell and Maddison, 1980) and 
coexistent Sjogren's syndrome or keratoconjunctivitis sicca (Reichlin 1985). 
Anti-Ro antibodies have also been associated with vasculitis (Reichlin 1985), 
hepatitis (reviewed in Craft and Hardin, 1992), decreased frequency of 
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Raynaud’s (Bell and Maddison, 1980) and non-thrombocytopenic purpura 
(Reichlin 1985); however, these associations have not been confirmed. 
Hamilton et al. studied antibodies to Ro, La, and Sm/nRNP in a 
group of SLE patients and identified two Ro autoantibody subgroups, 
associating the anti-Ro only group with HLA alleles DR2 and DQwl, and 
the anti-Ro and La subgroup with HLA alleles D8, DR3, DRw52, DQw2, 
older age at disease onset, sicca complex and less renal pathology 
(Hamilton et al., 1988). Anti-La antibodies are often associated with the 
sicca syndrome (reviewed in Craft and Hardin, 1992). 
Sm Anti-Sm antibodies are found in a higher frequency in blacks than 
whites (Arnett et al., 1988; Ward and Studenski, 1990) and have been 
associated with decreased frequency of CNS disease manifestations and 
nephritis (Swaak et al., 1990) (although this may be assay-dependent; 
reviewed in Craft and Hardin, 1992) and, in one study, an increased 
frequency of malar rash and hematologic pathology (Thompson et al., 1993). 
U1 snRNP Anti-Ul antibodies have also been associated with black race 
(Arnett et al., 1988). A study by Bell and Maddison looked at 64 patients and 
associated anti-Ul RNP with a lower frequency of serositis, renal disease, 
and Raynaud’s phenomenon (Bell and Maddison, 1980). Swaak et al., 
however, looking at a Netherlands' population found anti-Ul RNP 
correlated with an increased frequency of pleuropericarditis and CNS 
manifestations (Swaak et al., 1990); and Thompson et al., in 1993, found an 
association with increased frequency of Raynaud’s. Williamson et al 
correlated vasculitis with the presence of anti-Ul RNP (Williamson et al., 
1983). These correlations have yet to be widely confirmed. 
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Ribosomal Proteins Bonfa and Elkon, in 1986, associated anti-ribosome P 
antibodies with lupus psychosis using Western blotting technique. In 1990, 
Swaak suggested that these antibodies are also associated with sicca 
syndrome. 
Ki Tojo et al. suggested an association between anti-Ki antibodies and 
arthritis, pericarditis, fever, and pulmonary hypertension. Furthermore, 
an association between anti-Ki antibodies and a higher prevalence of CNS 
involvement has been suggested (Bernstein et al., 1984; Sakamoto et al., 
1989; reviewed in Swaak et al., 1990). 
PCNA Anti-PCNA antibodies have not been associated with any particular 
clinical symptoms (reviewed in Craft and Hardin, 1992). 
Autoantibody Sets 
The mutual occurrence of specific antibodies in sets has been evident 
to investigators since the first autoantibodies were reported. In 1973, 
Mattioli and Reichlin wrote a paper entitled “Physical Association of Two 
Nuclear Antigens and Mutual Occurrence of their Antibodies: the 
Relationship of the Sm and RNA Protein (Mo) Systems in SLE Sera” in 
which they discuss the mutual occurrence of Sm and U1 RNP 
autoantibodies. Since then, the occurrence of common autoantibodies in 
sets has been repeatedly confirmed. In addition to anti-Sm antibodies 
almost always accompanying anti-Ul RNP antibodies, anti-dsDNA 
antibodies often accompany anti-histone antibodies, and anti-La 
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antibodies/SS-B antibodies are almost always associated with anti-Ro 
antibodies (reviewed in Hardin 1986). Other sets identified include that 
antibodies to histones HI and H2B are almost always found together 
(reviewed in Hardin 1986) and that anti-U2 RNP antibodies are associated 
with anti-Ul RNP antibodies (Craft et al., 1988). Furthermore, these 
antibodies tend to occur in an ordered sequence (i.e., U1 RNP occurs before 
Sm and Ro before La) (reviewed in Hardin 1986). 
These sets are characterized by targeting particles that are a part of 
the same macromolecular structure, and as discussed by Hardin in 1986, 
“the most prominently recognized autoantigens reside on 3 types of 
nucleoprotein particles: the nucleosome, the U1 snRNP and the Ro scRNP 
[small cytoplasmic ribonucleoprotein] [sic].” These observations led Hardin 
and Tan to hypothesize independently that the immune response in SLE 
targets macromolecular particles (Hardin 1986, reviewed in Theofilopoulos 
1995). 
Etiology of SLE 
The etiology of the autoimmune response in systemic lupus 
erythematosus remains unclear. Epidemiological studies have suggested 
that susceptibility to lupus is multifactorial with investigations suggesting 
genetic, hormonal and environmental components to SLE (reviewed in 
Sinha et ah, 1990). Evidence supporting a genetic component includes that 
lupus is associated with the major histocompatibility complex (MHC) 
molecules HLA-B8, DR2, DR3, and DQwl (Maddison et al., 1985). 
(However, monozygotic twin pair studies show a concordance less than 
100% indicating that MHC genes are not the sole factor in determining 
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lupus) (reviewed in Sinha et al., 1990). A 9:1 female to male ratio in 
patients with SLE is well documented and strongly suggests a hormonal 
component to SLE. Other evidence for the role of sex hormones includes 
that testosterone enhances suppressor cell activity; estrogens have a 
stimulatory effect on B cells and a suppressive effect on regulatory cell 
activity; and lymphocytes respond with increased activity to pokeweed 
mitogen in the presence of estradiol and with decreased activity in the 
presence of testosterone (reviewed in Tsokos 1992). Current possibilities for 
the genesis of SLE, which will be briefly reviewed below, include: the 
particle hypothesis, the modified self hypothesis, the molecular mimicry 
model, polyclonal B and/or T cell activation, the release of anatomically 
sequestered antigens, the "cryptic self' hypothesis, the self-ignorance 
hypothesis, errors in B and/or T cell tolerance, and defects in 
immunoregulation (reviewed in Theofilopoulos 1995). 
The Particle Hypothesis As stated above, the autoantibodies of lupus 
patients commonly occur in sets (DNA/histone, Sm/Ul RNP, and Ro/La). 
These sets are characterized by targeting particles of common 
macromolecular structures: the nucleosome, the spliceosome and the Ro 
ribonucleoprotein. Such observations led to the hypothesis that the immune 
response in SLE targets macromolecular particles (Hardin 1986). The 
particle hypothesis of autoimmunization, proposed independently by Tan 
and Hardin, suggests that the total autoimmunogenic repertoire of lupus is 
localized on a limited number of subcellular particles (Hardin 1986, 
reviewed in Theofilpoulos 1995). 
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Modified Self Model In 1986, Hardin suggested that an inciting agent may 
structurally alter selected macromolecules, making them antigenic 
(Hardin 1986). In support of this modified self model, patients with drug- 
induced lupus target the same histone epitopes as patients with 
spontaneous lupus (Grayzel et al., 1991). 
Molecular Mimicry Model Infection has been shown to precede the onset of 
lupus which, together with the genetic predisposition, supports the 
molecular mimicry model. This model suggests that an exogenous agent 
bearing an epitope identical or similar to a host protein triggers an 
autoantibody response that may diversify (via cognate T cell - B cell 
interactions) to include autoantibodies to other epitopes on the inciting 
autoantigen or to an epitope on proteins of a multiprotein particle. Many 
studies support this theory. 
Lerner et al., in 1981, observed that certain Epstein-Barr encoded 
RNAs (EBER) are specifically precipitated by anti-La antibodies supporting 
the hypothesis that the immune response to La is triggered by binding of 
host proteins bearing these antigenic determinants to products of viral 
infection, the resultant complex being immunogenic (Lerner et al., 1981). 
Also, Chan et al. showed similarities between La and the adenovirus 72 kD 
DNA binding protein (Chan et al., 1986). Grayzel et al. studied the sera of 
polyvalent pneumococcal polysaccharide vaccinated nonautoimmune 
individuals showing a rise in anti-pneumococcal antibodies targeting DNA 
(anti-dsDNA associated idiotype) (Grayzel et al., 1991). Elkon et al. showed 
that the properties of the ribosomal protein autoantigen are similar to those 
of foreign protein antigens (Elkon et al., 1988). 
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Polyclonal B Cell Activation (PBCA) These above theories alone do not 
explain the observation that autoantibodies in the same patient may target 
proteins from separate intracellular particles (a significant number of 
patients have antibodies to cytoplasmic, cell surface and nuclear antigens) 
(Grayzel et al., 1991). The great diversity of autoantibodies in SLE is quoted 
as being one of the major pieces of evidence supporting polyclonal B cell 
activation as a primary feature in the pathophysiology of the lupus immune 
response (reviewed in Hardin 1986). Earlier models of PBCA suggested that 
it was secondary to intrinsic B cell hyperactivity or suppressor T cell 
deficiencies (reviewed in Hardin 1986). Current findings which support 
PBCA in SLE include: the number of B cells that secrete immunoglobulin is 
increased in lupus; the number of spontaneously activated B cells 
correlates with disease activity, serum-DNA binding and low levels of 
serum C3; and bone marrow from patients with SLE contains large 
numbers of B cells autonomously secreting immunoglobulin (reviewed in 
Tsokos 1992). 
Polyclonal T Cell activation (PTCA) On the other hand, a diversity of 
autoantibodies could also be secondary to intrinsic T-helper (Th) cell 
hyperactivity - PTCA. In various murine models, T cell contact is required 
for B cell production of polyclonal immunoglobulins (Fatenejad et al., 1993). 
Accordingly, anti-CD4 (a surface marker of Th cells) monoclonal antibodies 
prevent polyclonal Ig synthesis, and autoantigen-specific T cells are 
necessary for anti-dsDNA production (reviewed in Craft 1994 unpublished). 
Studies on human lupus patients have yielded isolated autoantigen-specific 
T cells (reviewed in Tsokos 1992). In 1993, a small clinical trial by Tokuda et 
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al. suggested that cyclosporin A (CsA), an inhibitor of Th and cytotoxic cell 
activation, reduces the disease activity of SLE (Tokuda 1994). 
Release of Anatomically Sequestered Antigens Interestingly, many 
antigens in lupus are intracellular and are in "privileged" sites that are 
normally inaccessible to circulating autoantibody. Hardin suggested that 
these intracellular particles may be protected by lower levels of tolerance 
(Hardin 1989). It is unclear how such intracellular antigens become 
involved in pathogenesis; however, studies have shown that intracellular 
molecules can escape autolytic degradation and be released into the 
extracellular environment. These molecules are then capable of being 
targeted by preexisting circulating antibody. This is seen in lupus when 
anti-dsDNA antibodies complex with DNA and initiate pathology. 
Furthermore, other normally intracellular antigens have been located 
extracellularly. Ro and Sm have been identified on keratinocytes and Sm is 
expressed on the cell surface in the kidney in some patients, (reviewed in 
Tan 1991) 
"Cryptic Self' Hypothesis As explained in a recent review by 
Theofilopoulos (1995), this theory is based on the concept that MHC 
molecules usually process and present "self-determinant" proteins which 
constitute the dominant self. The immune system is normally tolerant to 
these self-proteins, but there are poorly displayed cryptic determinants 
which do not induce tolerance. Cryptic epitopes, generated by aberrant 
antigen processing of self or foreign polypeptides, may thus activate 
autoreactive cells and promote autoantibody production. For example, 
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cytochrome C peptide has been shown to contain a "cryptic" peptide 
(Mamula 1993). 
Self-ignorance Hypothesis The self-ignorance hypothesis suggests that T 
cells specific for extrathymic antigens undergo anergy because of the 
absence of appropriate "costimulatory" factors. A popular model for this 
theory is that a virus, such as coxsackievirus or mumps, upregulates MHC 
and costimulatory factors, and contributes to (3 islet cell destruction in 
diabetes mellitus (Hou et al., 1993; Gerling et al., 1991; Loria et al., 1984; 
Parkkonen et al., 1992; Szopa et al., 1993; Vuorinen et al., 1992). 
T and/or B Cell Tolerance Defect This theory suggests that in the normal 
host, autoreactive T and/or B cells are present but by some mechanism are 
tolerant. A defect in this mechanism could hypothetically result in a 
polyclonal autoantibody response. Various evidence has been accumulated 
to support this theory. For example, SLE-prone lpr mice are defective in the 
Fas apoptosis gene and have activated autoreactive T and B cells due to a 
defect in peripheral programmed cell death, (reviewed in Theofilopoulos 
1995) 
Immunoregulatory Disturbances Certain T cell regulatory subsets have 
been suggested to induce or inhibit disease development. Specifically, 
(A) Defects of T-suppressor lymphocyte function may be involved in 
the pathogenesis of SLE. In support of this theory, the absolute number of T 
lymphocytes in SLE patients is decreased whereas peripheral B 
lymphocytes are present in normal number. More specifically, SLE 
patients have a decrease in the suppressor/cytotoxic lymphocyte 
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subpopulation, as defined by the presence of cell surface markers. 
Furthermore, Tar cells, which are considered to be precursors of 
suppressor/effector cells, are decreased in SLE. Low activity of natural 
killer cells, which are known to suppress B cell function and kill virus- 
infected cells, is associated with SLE disease activity. Also, some studies 
have shown that concanavalin A-induced suppressor cell function in 
patients with SLE is deficient. Deficient suppressor cell activity has been 
shown to correlate with SLE disease activity, serum DNA binding and low 
serum C3 levels. Epstein-Barr virus associated suppressor/cytotoxic cell 
function in EBV seropositive SLE patients has also been shown to be 
defective, supporting a secondary infectious component in addition to a 
primary defect in immunoregulation. (reviewed in Tsokos 1992) 
(B) Increased T-helper activity has also been considered a possible 
etiologic theory. Evidence for this theory comes from several sources. 
First, patients with active SLE have been shown to have increased 
expression of DR antigens on the surface of their T cells. DR+ cells provide 
help to autologous B cells to secrete immunoglobulin. Furthermore, in 
several lupus patients and some murine models of lupus, T cell 
subpopulations which provide help to B cells to secrete immunoglobulin 
have been isolated. For example, the CD3+CD4'CD8‘ subpopulation in SLE 
patients with active disease have been shown to provide help to autologous B 
cells to secrete anti-dsDNA antibodies, whereas normal controls failed to do 
so. (reviewed in Tsokos 1992) 
Problems with the theory of a defect in immune regulatory cells 
include that anti-T-lymphocyte antibodies have been noted in lupus and that 
anti-dsDNA antibodies have been found to bind surface structures of 
normal human T cells. Consequently, the decreased number of 
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lymphocytes in SLE may be a result and not a cause of lupus, (reviewed in 
Tsokos 1992) 
The above etiologic theories can be grossly divided into two main 
categories: those that support a global defect in immune tolerance versus 
those that support a single immunogen-guided response. Because a 
limited number of autoantigens appear targeted in SLE, autoantibody 
profiles can be examined hoping to support one main theory. A simple way 
of addressing this question is to ask how many different immunogens a 
single patient's serum targets. Two studies in the past have addressed the 
average number of antibody specificities per patient: in 1975, Notman and 
Tan found nine SLE patients had three or four individual specificities 
(Notman et al., 1975). This was confirmed by Boey and Tan in 1988 who 
found an average of 2.9 antibodies per SLE patient. The presence of more 
than one autoantibody per patient could be used to support a global defect in 
tolerance; however, given the hypothesis by Hardin and Tan that the 
autoimmune response targets particles (e.g., the nucleosome, the Ro/La 
RNP particle, the spliceosome), it may be more relevant to examine the 
number of autoantibody sets, not individual specificities, per patient. This 
question has not been previously addressed in the literature. The present 
study addressed this question by immunologically studying a group of SLE 
patients followed at Yale University and the surrounding New Haven area, 
as well as reanalyzing the autoantibody profiles previously reported in the 
literature. The sensitive and specific methods of ELISA and 
immunoprecipitation were used to determine the specificities of each 
patient's serum. Since this patient population was previously unstudied, 
the prevalence of defined autoantibodies are reported, and 
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autoantibody/clinical correlations were examined to study if associations 




Common antigens in systemic lupus erythematosus. 
Cellular antigen Characteristics Frequency in SLE Reference 
dsDNA Nucleic acid 
ssDNA Nucleic acid 
Histones HI, H2A, H2B, H3-4 proteins 
Sm mRNA processing 
Ul, U2, U4-6 snRNA 
B,B\ D, E proteins 
U1 RNP mRNA processing 
Ul snRNA 
70 kD, A, C proteins 
Ro/SSA RNA processing 
60kD, 52kD proteins 
Y1-Y5 RNA 
La/SSB RNA polymerase III 
termination complex 
46kD, 48kD phosphoproteins 
RNA 
Ribosomal P Protein translation 
proteins 38kD, 16kD, 15kD 
phosphoproteins 
PCNA/cyclin DNA replication 
36kD protein 
Ku 86kD, 66kD nuclear protein 
SL/Ki 32kD protein 
40 Tan 1989 
70 Tan 1989 
30-70 Swaak et al., 1990 
Tan 1989 
15-30 Swaak et al., 1990 
Tan 1989 
32 Boey et al., 1988 
25-35 Tan 1989 
Reichlin 1985 
15 Tan 1989 
10-15 Bonfa and Elkon, 
1986 
Christian and Elkon, 
1986 
Elkon et al., 1988 
3/7.9-21.4 Boey et al., 1988 
Swaak et al., 1990 
Sakamoto et al., 1989 
5-10 Boey et al., 1988 
Tan 1989 
Sakamoto et al., 1989 
6.3-21 Boey et al., 1988 
Bernstein et al., 1984 
Reichlin 1985 
Swaak et al., 1990 




Clinical correlations found in autoantibody profile studies in the literature. 
Antibody Clinical/Lab Association References 
dsDNA Nephritis, negative CNS, malar rash, 
renal, hematologic, hypocomplementemia 
Thompson et al., 1993 
Swaak et al., 1990 
Histone Photosensitivity, drug induced lupus Thompson et al., 1993 
Swaak et al., 1990 
Ro HLA-B8/DRw3, skin rash, RF positivity 
Congenital heart block, neonatal lupus 
photosensitivity, Sjogren's syndrome 
subacute cutaneous lupus, hepatitis 
vasculitis, thrombocytopenic purpura 
HLA-DR2/DQw 1 
Bell and Maddison,198( 
Maddison et al., 1985 
Thompson et al., 1993 
Craft and Hardin, 1992 
Thompson et al., 1993 
Reichlin, 1985 
Hamilton et al., 1988 
La CNS, rashes, photosensitivity, Sicca syndrome, 
negative nephritis, HLA-D8/DR3/DRw52/DQw2 
Craft and Hardin, 1992 
Maddison et al., 1985 
Hamilton et al., 1988 
Thompson et al., 1993 
Swaak et al., 1990 
Sm Negative CNS or nephritis, malar rash 
renal, hematologic, hypocomplementemia 
Thompson et al., 1993 
Swaak et al., 1990 
U1RNP Vasculitis 
CNS, pleuropericarditis 
negative serositis, renal disease, and Raynaud’s 
increased Raynaud’s, hematologic 
Williamson et al., 1983 
Swaak et al., 1990 
Bell and Maddison, 198( 
Thompson et al., 1993 
Ki CNS, arthritis, pericarditis, pulmonary HTN, fever Sakamoto et al., 1989,31 
Ribosomal P proteins Sicca syndrome, lupus psychosis Swaak et al., 1990 
Bonfa and Elkon, 1986 
Other 
Ro and U1RNP”-” Less Raynaud’s Bell and Maddison, 198( 
dsDNA &/or Sm Proteinuria, renal casts, leukopenia, Thompson et al., 1993 
lymphopenia, thrombocytopenia, 
hypocomplementemia, malar rash, 
increased prevalence and severity of clinical manifestations 
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PATIENTS AND METHODS 
Sera. Serum samples from 68 patients with systemic lupus erythematosus were 
obtained from the Division of Rheumatology, Department of Medicine, Yale University. 
All patients were diagnosed with SLE based on fulfilling at least four of 11 of the American 
Rheumatology Association's 1982 Revised Criteria for the Classification of SLE. 
Sera from 11 lab technicians were used as normal controls. Prototype sera 
containing antibodies to Ro, La, U1 RNP , Sm, dsDNA, histones, Ku, Ki, PCNA, and 
ribosomes were previously obtained by Dr. Joseph Craft. Six negative human plasma 
controls and six standard human plasma controls containing antibodies to Ro, La, U1 
RNP, Sm, dsDNA, and histones were obtained from Apotex Scientific, Inc. 
ELISAs. Kits were obtained from Apotex Scientific, Inc., and sera were tested 
as per protocol outlined by Apotex. Patient and control sera were diluted (1:500 for Ro, 
La, Ul, and Sm; and 1:100 for DNA and histones) in phosphate, BSA and 0.5% sodium 
azide buffer and incubated with antigen for 60 minutes. Coated wells were washed with 
borate and 0.8% sodium azide buffer three times, and antigen-antibody product was 
labeled with alkaline phosphatase labeled anti-human IgG murine monoclonal antibody for 
30 minutes. After three washes with borate buffer, labeled antigen-antibody complexes 
were developed with Mg2+/phenolphthalein monophosphate substrate for 30 minutes. The 
alkaline phosphatase enzyme reaction was stopped with EDTA solution and the absorbance 
was read at 550nm (Titertek Multiskan model 310 spectrometer). 
Preparation of radiolabeled cell extract. HeLa cell extract was prepared as 
previously described (Craft and Hardin 1992). HeLa cells were radiolabeled for 8-14 
hours with 35S-methionine (5uCi/ml of cells; ICN Biomedical, Irvine, CA), collected by 
centrifugation for 10 minutes at l,000g, washed in 10-12 pellet volumes of Tris-buffered 
saline (TBS; lOmM Tris-Cl, pH 7.4, 150mM NaCl), and resuspended in 
immunoprecipitation buffer (IPP; lOmM Tris-Cl, pH 8.0, 500mM NaCl, 0.1% Nonidet P- 
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40). Resuspended labeled cells were sonicated 3 times each for 30 seconds with a Branson 
sonifier at setting 3, centrifuged for 15 minutes at 15,000g 4° C to remove cellular debris, 
and the supernatant was collected. 
Immunoprecipitation of radiolabeled cell extracts. Immunoprecipitation 
of radiolabeled cell extract was performed as previously described (Craft and Hardin 
1992). Five pi patient or 1-5 pi control sera and 2 mg protein A-Sepharose CL-4B 
(Pharmacia, Piscataway, NJ) were combined in 400 ul IPP buffer by end-over-end 
rotation (Labquake Shaker; Lab Industries, Berkeley, CA) for two hours at 4° C. After 
three washes with IPP buffer, the antibody-coated Sepharose beads were resuspended in 
400 pi IPP buffer and combined with 50-100 pi 35S labeled cell extract by end-over-end 
rotation for 2 hours at 4° C. Antibody-protein complexes were washed three times with 
cold IPP buffer, resuspended in 3 to 4 pellet volumes of SDS-sample buffer (2% SDS, 
10% glycerol, 0.5M Tris Cl/0.4% SDS, pH 6.8, mercaptoethanol, 0.005% bromphenol 
blue); and after vortexing and heating at >95° C for 5 minutes, the proteins were 
fractionated on SDS polyacrylamide gels. The gels were enhanced with 0.5M sodium 
salicylate, dried and analyzed by autoradiography. Results were based on comparison with 
prototypic sera (Figures 1,2 and 3). 
Meta-analysis. A literature search was carried out and previously reported 
autoantibody profiles of SLE patients were analyzed. The minimal average number of 
autoantibody sets per patient was calculated based on the reported data. In studies assaying 
for only several autoantibodies, the calculated average number of autoantibody sets per 
patient may grossly underestimate the actual number of sets. 
Clinical Evaluation. Patients were evaluated by retrospective clinical chart 
review (raw data collected largely by Dr. Robert McClean, Rheumatology Fellow at the 
Yale University School of Medicine). All 68 patients included in the study were diagnosed 
with SLE according to the ARA's 1982 Revised Criteria. Clinical information on patients 
was cumulative and not necessarily obtained solely at the time sera were drawn. 
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Dermatologic disease was diagnosed by the presence of malar rash, 
photosensitivity, alopecia, mucous membrane ulcers, discoid rash, livedo reticularis, 
subcutaneous nodules, and/or clinically reported symptoms of sicca syndrome. Serositis 
was diagnosed clinically and/or radiologically. Musculoskeletal disease was defined by 
arthritis involving two or more peripheral joints, clinically reported myalgias or arthralgias, 
and/or myositis accompanied by elevated muscles enzymes. Neurological disease included 
clinical psychosis, peripheral neuropathy, and/or seizures in the absence of drugs or other 
known metabolic causes. Vascular disease was defined by clinically reported Raynaud’s, 
vasculitis, cutaneous vasculitis, deep venous thrombosis by Doppler ultrasound, and/or 
digital or leg ulcerations thought secondary to vascular pathology. Renal disease was 
diagnosed histologically, on the basis of persistent proteinuria (>0.5gm/day), and/or 
cellular cast(s) on urinalysis. Hematologic disorders were defined by hemolytic anemia 
(documented by positive Coombs and/or reticulocytosis), leukopenia (<4,000/mm3), 
lymphopenia (< 1,500/mm3), and/or thrombocytopenia (<100,000/mm3). 
Hypocomplementemia and rheumatoid factor positivity were defined according to 
individual laboratory guidelines. 
Sample size was determined by a nomagram, using the standard difference (SD) of 




where pi and p2 are the expected proportions of events in the experimental and control 
groups, respectively, and pm is the mean of the proportions ((pi + p2)/2). The number of 




The experimental and control specimens were not equivalent in number; therefore, a 
correction for power was made. The method of estimating the sample size for a given 
power estimation used was: 
N = N'(l + k)2 
4k 
where k = the ratio of experimental specimens to control specimens and N' = the original 
sample size (n) required as determined by nomogram. 
Given 68 experimental patients and 12 control patients, k = 5.7. The adjusted 
sample size is (rearranging the above equation): 
N (4) k 
(1 + k)2 
or 41. By nomagram, this gives a SD of approximately 0.875 for a significance of 95% (a 
= 0.05). 
By empirically testing pfs, the SD equals 0.84 for a prevalence of 30%. Hence, 80 
patients containing 12 control patients supplied enough specimens to determine statistical 
significance at 95% confidence and 80% power, as long as the prevalence of the tested 
autoantibody or clinical characteristic was 30%. (If 68 negative controls would have been 
run, a prevalence of 10% would have been statistically significant.) 
Clinical/autoantibody associations were determined using Chi-square analysis with 
Yates' correction. A resulting P-value < 0.05 was considered significant. Clinical 
manifestations and antibodies with a frequency > 10% in the study population were 
analyzed, however only the tested entities with a frequency of > 30% have a statistical 




The Study Population Sixty-eight patients fulfilling the ARA Revised 
Criteria for systemic lupus erythematosus were studied (Table 3). The 
female to male patient ratio was 9:1. The white to black patient ratio was 
3:1. The mean age at disease onset was 30.2 +/- 13.9 years. One quarter of 
the patients reported a first degree relative as having either rheumatoid 
arthritis (RA) or SLE. The mean duration of disease at the time the sera 
samples were drawn was 8.2 years. The mean duration of disease at the 
time of the chart review was 10.9 years. 
Clinical Aspects Initial clinical factors are shown in Table 4. Possible 
precipitating events identified include pregnancy in nine patients and 
infection in two patients. The initial clinical signs/symptoms reported 
include, in decreasing order of frequency: arthralgias, arthritis, rash, 
ITP, fatigue, serositis, Raynaud's, extremity weakness, alopecia, 
photosensitivity, subcutaneous nodules, myalgias, aseptic meningitis, 
cutaneous vasculitis, proteinuria, hemolytic anemia, dyspnea, and chest 
pain. Fourteen patients had greater than or equal to two initial signs or 
symptoms. 
Cumulative frequencies of the individual clinical manifestations of 
SLE in the study population are shown in Table 5. Chi-square analysis with 
Yates' correction was used to study associations between autoantibodies 
and SLE clinical manifestations. Those clinical manifestations and 
antibodies of > 10% frequency in the study population were considered, 
including: dermatologic disease as a whole (malar rash, alopecia, 
photosensitivity, mucous membrane ulcers, discoid rash, livedo reticularis, 
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sicca syndrome, and/or subcutaneous nodules), malar rash, alopecia, 
photosensitivity, mucous membrane ulcers, discoid rash, serositis as a 
whole (pleuritis and/or pericarditis), musculoskeletal disease as a whole 
(arthritis, arthralgias, myalgias, and/or myositis), arthritis, neurological 
manifestations of disease as a whole (psychosis, peripheral neuropathy, 
and/or seizures), Raynaud’s, vasculitis, cutaneous vasculitis, history of a 
thrombotic event, renal disease as a whole (proteinuria, RBC casts in 
urine, and/or renal failure), proteinuria, RBC casts in urine, hematologic 
disease as a whole (leukopenia, hemolytic anemia, and/or 
thrombocytopenia), leukopenia, hemolytic anemia, thrombocytopenia, 
hypocomplementemia, rheumatoid factor positivity, and corticosteroid 
treatment at the time of phlebotomy. 
The following entities were not studied because of either a lack of 
statistical power of 80% secondary to a frequency less than 10% or a 
subjective lack of utility: livedo reticularis, sicca syndrome, subcutaneous 
nodules, pericarditis, myalgias, myositis, seizures, vascular disease as a 
whole, digital ulcerations, leg ulcerations, renal failure, lymphopenia, 
VDRL false positivity, headache, and thyroiditis. 
The associations found are shown in Table 5. A P value < 0.05 for a 
confidence level > 95% was considered statistically significant. Notable 
findings by autoantibody follow. Anti-dsDNA antibodies were associated 
with serositis, pleuritis ((3 > 0.20), musculoskeletal disease manifestations, 
arthritis, renal disease, and hypocomplementemia. No association 
between dsDNA antibodies and CNS disease was found. Anti-histone 
antibodies were associated with discoid rash ((3 > 0.20), serositis, 
musculoskeletal disease manifestations, leukopenia, thrombocytopenia ((3 > 
0.20), and hypocomplementemia. Anti-Sm antibodies were associated with 
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serositis and pleuritis (|3 > 0.20). No association between race and Sm was 
shown ((3 > 0.20). Anti-Ul RNP antibodies correlated with cutaneous 
disease, serositis, and pleuritis ((3 > 0.20). Anti-Ro antibodies were 
associated with neurological disease and hemolytic anemia. No correlation 
between anti-Ro antibodies and RF positivity was found. Anti-La antibodies 
were associated with RF positivity. 
Forty-three percent of the study population were receiving 
corticosteroid treatment at the time of phlebotomy. Corticosteroid treatment 
correlated with autoantibodies to histones, dsDNA and/or Ro. 
Inter-autoantibody associations were studied (Table 6). Anti-histone 
antibodies associated with anti-dsDNA antibodies, anti-Ul RNP antibodies, 
and weakly with anti-Ro antibodies. Anti-dsDNA antibodies were also 
associated with anti-Ul RNP antibodies and anti-Sm antibodies. Notably, 
anti-Sm antibodies did not statistically correlate with anti-Ul RNP 
antibodies, however, the chi-squared analysis is not statistically significant 
at an Sm frequency of 14.7%. The study did show that 6 of 10 Sm positive 
patients had the U1 RNP specificity as well. Anti-Ro and anti-La antibodies 
were statistically associated. 
Autoantibodies Sera of the 68 SLE patients and 12 controls were studied by 
ELISA and immunoprecipitation for the following autoantibody 
specificities: dsDNA, histone, Sm, U1 RNP, Ro, La, rRNP, PCNA, Ku, Ki, 
and other autoantibodies (unidentified band(s) by immunoprecipitation). 
The following autoantibody sets were considered: dsDNA and/or histone, 
Sm and/or U1 RNP, Ro and/or La, rRNP, PCNA, Ku, Ki, and other 
(unidentified protein bands on SDS polyacrylamide gels after 35S 
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immunoprecipitation). The results by patient number and frequency 
percent are shown in Tables 7 and 8. 
Autoantibody frequency (%) results by ELISA include: anti-dsDNA 
39.7%, anti-histone 51.5%, anti-Sm 14.7%, anti-Ul 33.8%, anti-Ro 39.7%, 
and anti-La 14.7%. Autoantibody set results by ELISA include: anti- 
dsDNA and/or anti-histone 58.8%, anti-Sm and/or anti-Ul RNP 39.7%, and 
anti-Ro and/or anti La 41.2%. 
Using 35S immunoprecipitation, the following specificities in 
frequency percent resulted: anti-Ro 42.6% and anti-La 19.1%. By 
autoantibody set, the following frequencies were found: anti-Sm and/or 
anti-Ul RNP 39.7%, and anti-Ro and/or anti-La 44.1%. Protein bands on 
SDS polyacrylamide gels similar to those found in prototypic sera with 
specificities for ribosomal proteins, Ku, and Ki were found in the following 
percentages, respectively: 4.4%, 4.4%, and 2.9%. These frequencies are not 
sufficiently high for significant statistical analysis as stated previously. 
Fourteen (20.5%) patients had protein bands of unidentified specificities. 
Eleven patients (16%) were autoantibody negative by both ELISA and 
immunoprecipitation. All positive control plasma samples were positive 
for respective specificities by ELISA. All negative control plasma and sera 
were autoantibody negative by ELISA. By immunoprecipitation, no 
negative control sera had autoantibodies to Sm/Ul RNP, Ro, La, rRNP, 
PCNA, Ku or Ki. Three normal control sera had protein bands of 
unidentified specificity. 
The average number of antibodies and antibody sets per patient were 
determined as 2.34-2.37 and 1.72-1.74, respectively (Table 9). Considering 
only antibody positive patients, the average number of antibodies and 
antibody sets per patient were 2.79-2.82 and 2.01-2.07, respectively. The 
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distributions of the number of antibodies and antibody sets per patient are 
shown in Figures 4 and 5. Using ELISA and immunoprecipitation results: 
twelve patients each had one, two, or three autoantibodies; thirteen patients 
had four antibodies; five patients showed five antibodies; and two patients 
had six antibodies. By antibody set: 17 patients had one set, 19 patients had 
two sets, 14 patients had three sets, and five patients had four autoantibody 
sets. (Table 8) 
The number of autoantibody sets by duration of disease at the time of 
phlebotomy was plotted (Figure 6). No correlation was shown. 
Autoantibody profiles found in the literature are shown in Table 8. 
Data sets were analyzed for the minimal possible number of reported 
antibody sets per patient (Table 10). Twelve studies found at least greater 
than than one set per patient, three studies found at least greater than two 





Characteristics of the study group. 
Total number of patients = 68 
Sex Female 61 (90%) 
Male 7 (10%) 
Race White 42 (62%) 
Black 15 (22%) 
Hispanic 1 (1.5%) 
Unknown 10 (15%) 
Mean age at disease onset (years) = 30.2 SD +/- 13.9 
Median age at disease onset (years) = 29.0 
Mean duration of disease at time of phlebotomy (years) = 8.2 
Mean duration of disease at time of chart review (years) = 10.9 




Initial Clinical Factors. 
Possible precipitating event 
Pregnancy 
Infection 












































Clinical profile ofSLE patient population. 
Disease manifestation No. with 
diagnosis 
Frequency 
of occurrence (%) 
Antibody association P 
Cutaneous 55 81% U1 RNP <.05 
malar rash 34 50 
alopecia 28 41 
photosensitivity 27 40 
mucous membrane 
ulcers* 19 28 
discoid rash* 8 12 His <.05 
livedo reticularis*1 4 6 
sicca syndrome ** 2 3 
subcutaneous 
nodules *' 2 3 
Serositis 24 35 dsDNA <.01 
Sm <.01 
U1 RNP <.05 
His <.05 
pleuritis* 18 27 dsDNA <.01 
U1 RNP <.05 
Sm <.05 
pericarditis*1 6 9 
Musculoskeletal 57 84 His <.05 
dsDNA <.05 
arthritis 48 71 dsDNA <.05 
arthralgias1 27 40 
myalgias*1 6 9 
myositis*1 3 4 
Neurological manifestations 22 32 Ro <.02 
psychosis* 12 18 
peripheral neuro* 7 10 
seizures*1 2 3 
Vascular1 35 52 
Raynaud's 21 31 
vasculitis 21 31 
cutaneous vasculitis* 16 24 
thrombotic event* 7 10 
digital ulcerations*1 6 9 
leg ulcerations*1 1 2 
Renal 30 44 dsDNA <.05 
proteinuria 27 40 
RBC casts in urine 22 32 
renal failure*1 6 9 
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Table 5 (continued) 
Disease manifestation No. with 
diagnosis 
Frequency 
of occurrence (%) 
Antibody association P 
Heme1 43 63% 
leukopenia <4K 25 37 His <.05 
hemolytic anemia* 20 30 Ro <.02 
thrombocytopenia * 12 18 His <.05 
(<100K) 
lymphopenia *1 4 6 
(<1.5K) 
Constitution symptoms' 40 59 
fatigue1 34 50 
fever1 21 31 
wt loss (>5 lb.)*1 8 12 
Other 
Hypocomplementemia dsDNA <.01 
His <.02 
low C31 32 67 
low C41 30 63 
Rheumatoid Factor * 9 41 La <.01 
(out of 22 patients) 
VDRL false "+" *' 5 29 
(out of 17 patients) 
HA*1 8 12 
thyroiditis *' 5 7 
Corticosteroid Tx 29 43 His <.01 
dsDNA <.01 
Ro <.05 
* (3 > 0.20 





Antibody Associated Antibody Chi-Squared P 
Histone dsDNA 19.0 <.001 
U1 RNP 13.6 <.001 
Ro 3.86 <.05 
dsDNA Histone as above 
U1 RNP 6.58 <.02 
Sm 4.37 <.05 
Sm dsDNA as above 
U1 RNP 2.92* <.l 
U1 RNP Histone as above 
dsDNA as above 
Sm as above 
Ro La 3.86 <.05 
Histone as above 





Autoantibody profiles (Part I). 




dsDNA 27 40% 
Histone 35 52 
dsDNA/Histone set 40 59 
Sm* 10 15 
U1 RNP 23 34 
Sm/Ul RNP set 27 27 40 40% 
Ro 27 29 40 43 
La* 10 13 15 19 
Ro/La set 28 30 41 44 
?rRNP* 3 4 
?PCNA* 0 0 
?Ku* 3 4 
?Ki* 2 3 
?Other 14 21 
High Band (HB) A 170 kD 3 
HBB 125 kD 1 
HB C 100 kD 1 
HB D 98 kD 1 
HB E 97 kD 1 
HB F 78 kD 1 
HB G 75 kD 1 
HB I 70 kD 1 
Low Band (LB) A 43 kD 1 
LB B 35 kD 1 
LB C 17 kD 1 
Three bands 1 




Autoantibody profiles (Part II). 
Number of antibodies Number of patients Frequency (%) of pts 
or set(s) ELISA 1PP ELISA IPP 
1 antibody 14 12 21% 18% 
2 antibodies 11 12 16 18 
3 antibodies 13 12 19 18 
4 antibodies 11 13 16 19 
5 antibodies 5 5 7 7 
6 antibodies 2 2 3 3 
1 antibody set 18 17 27 25 
2 antibody sets 20 19 29 28 
3 antibody sets 13 14 19 21 
4 antibody sets 5 5 7 7 
Autoantibody neg. patients* 11 11 16 16 
*p > 0.20 
Table 9 
Autoantibodies or antibody sets per patient. 
ELISA IPP 
Average number of antibodies/ patient 2.34 2.37 
Average number of antibodies/autoantibody positive patient 2.79 2.82 
Average number of antibody sets/patient 1.72 1.74 





Autoantibody profiles in the literature. 
Author Autoantibody Frequency (%) Antibody sets/pt 
dsDNA His Sm U1RNP Sm/Ul Ro La 
This study 1.72 
68 pts 
Arnett (1988)2’3-4 
40 52 15 34 40 40-43 15-20 
>1.1 
60 Black pts 25 40 52 58 20 
106 White pts 
Bell and Maddison (1980)5 
10 23 26 45 20 
>1.08 
64 White pts 
Bernstein et al. (1984)4 
61 22 25 2.5 25' 
270 pts 
Boey et al. (1988)6 
7 23 24 8 
94 Asian pts 43 81 26 32 63 12 >2.09 
9 psych pts 
Bonfa and Elkon (1986)4 7 
88 100 77 66 >3.64 
i-RNP “+” pts 
18 psych pts 44 33 33 50 11 >2.27 
14 nonpsych pts 
Hamilton et al. (1988)2 3-4 
50 36 36 36 0 >2.22 
106 White pts 
Hochberg (1985)8 9 
10 23 26 45-37 21-11 
150 pts 
113 White pts 27 15 32 33 12 >1.8 
37 Black pts 30 24 41 30 11 >1.95 
Jayaram (1990)4-8 
30 Indian pts 
Juby (1991 )2 9 
30 73 27 63 
>1.36 
108 Canadian pts 
Kiparski (1990)4 
22 1 21 36 17 7 
(rev in Swaak et al.) 
Maddison et al. (1985)2-3 
10 20 37 14 
63 UK pts 
Notman (1975)1 
17-33 30-46 33-55 15-24 
50 pts 
Scopelitis et al.(1980)iau 
70 52 28 26 
>1.43 
73 Black pts 
Speransky (1988)4-10 
74 32 40 29 0 
>1.31 
107 USSR pts 
Swaak (1990)4'10’12 
54 21 27 50 48 
>1.03 
164 Netherlands 76 9-22 9-29 12-28 18-45 
Westgeest (1990)4 
(rev in Swaak et al.) 8-29 8-14 10-16 
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Table 10 (continued) 
Author Autoantibody Frequency (%) Antibody sets/pt 
dsDNA His Sm U1RNP Sm/Ul Ro La 
Williams (1990)2 * 4 * 
(rev in Swaak et al.) 19 25 47 5 
Williamson et al.(1983)6 * * * * 11 




-'radioimmunoassay and precipitin analysis 
^immunoprecipitation 









Figure 1. 35S Immunoprecipitation of standard sera of the following 
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Figure 2. 35S Xmmunoprecipitation of ribosomal control sera (lanes 




Figure 3. Sample 35S Immunoprecipitation of study population sera 
showing: MW standard, Sm, Sm, no autoantibodies, no 




Distribution of the number of autoantibodies per patient. 
Figure 4. Sera of 68 patients fulfilling the 1982 Revised Criteria for the 
Classification of Systemic Lupus Erythematosus were assayed by 35S 
immunoprecipitation and ELISA for autoantibodies (dsDNA, histone, Ro, La, 
Sm, U1 RNP, rRNP, PCNA, Ku, Ki, and/or other) and the number of 
autoantibodies in each patient serum was calculated. The distribution of the 












Distribution of the number of autoantibody sets per patient. 
Figure 5. Sera of 68 patients fulfilling the 1982 Revised Criteria for the 
Classification of Systemic Lupus Erythematosus were assayed by 35S 
immunoprecipitation and ELISA for autoantibody sets (dsDNA/histone, Ro/La, 
Sm/Ul RNP, rRNP, PCNA, Ku, Ki, and/or other) and the number of 
autoantibody sets in each patient serum was calculated. The distribution of the 




Number of autoantibody sets by duration of disease at phlebotomy. 
Figure 6. Sera of 68 patients fulfilling the 1982 Revised Criteria for the 
Classification of Systemic Lupus Erythematosus were assayed by 35S 
immunoprecipitation and ELISA for autoantibody sets (dsDNA/histone, Ro/La, 
Sm/Ul RNP, rRNP, PCNA, Ku, Ki, and/or other). The duration of disease at 
time of phlebotomy for each patient was determined by chart review. Each 





Using both 35S immunoprecipitation and ELISAs, the autoantibody 
profiles of 68 patients fulfilling the ARA Revised Criteria for systemic lupus 
erythematosus were determined. Additionally, autoantibody profiles of SLE 
patients previously reported in the literature were reviewed and analyzed. 
The clinical manifestations of disease in the study population were collected 
through clinical chart review, and Chi-square analysis was used to study 
possible associations between individual autoantibodies, and between 
autoantibodies and clinical manifestations. 
The prevalence of antibodies to dsDNA (40%), histones (52%), Sm 
(15%), U1 RNP (34%), Ro (40-43%), and La (15-19%), found using both 35S 
immunoprecipitation and ELISA, in this previously unreported population 
are consistent with the literature (Table 1). This confirms that a high 
uniformity of antibody specificities exists between different populations. 
Associations between clinical disease manifestations and 
autoantibody specificities previously reported in the literature and 
confirmed in this study include the following: anti-dsDNA antibodies and 
renal pathology; anti-dsDNA and hypocomplementemia; and anti-Ul 
antibodies and serositis. Associations previously reported in the literature 
which were not found in this study include the following: anti-dsDNA 
antibodies and neurologic disease, malar rash, or hemolytic disease; anti¬ 
histone antibodies and photosensitivity; anti-Ro antibodies and rheumatoid 
factor positivity, vasculitis, or thrombocytopenia; anti-La antibodies and 
CNS disease, or protection against renal disease; anti-Ul RNP antibodies 
and vasculitis; and anti-Sm antibodies were not protective against CNS or 
renal diseases. Interestingly, anti-La antibodies, not anti-Ro antibodies, 
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correlated with RF positivity which, if the particle hypothesis is true, would 
support an association between the Ro/La set and RF positivity. Also, anti¬ 
histone antibodies, as well as anti-dsDNA antibodies, correlated with 
hypocomplementemia. Interestingly, anti-Ro antibodies were the only 
antibodies associated with CNS manifestations of disease. 
Additionally, the more prevalent autoantibodies correlated with the 
more prevalent clinical manifestations, anti-dsDNA antibodies correlated 
with musculoskeletal disease and serositis, anti-histone antibodies 
correlated with many clinical manifestations (hemolytic disease, serositis, 
and musculoskeletal disease), and anti-Ro antibodies correlated with 
hemolytic disease. Because of the high prevalence of these antibodies and 
disease manifestations, these associations may be coincidental. 
Corticosteroid treatment correlated with anti-dsDNA, anti-histone, and 
anti-Ro antibodies (the three most prevalent antibodies), indirectly 
suggesting that patients with these particular antibodies, or patients with 
higher numbers of antibodies, may have more severe disease. 
The role of specific autoantibodies in the pathogenesis of the clinical 
manifestations has long been hypothesized. The present study did not 
directly address the role of autoantibodies in the pathogenesis of SLE. 
However, in the present study, anti-dsDNA antibodies correlated with 
hypocomplementemia and renal pathology which is consistent with a role 
of dsDNA in the pathogenesis of lupus renal disease. (As stated previously, 
it is generally believed that anti-dsDNA antibodies form immune complexes 
which lead to renal injury.) This study did not address a correlation 




Confirmed in this study are previously reported autoantibody set 
patterns of the autoimmune response: Ro with La, and dsDNA with histone 
(all anti-La sera, except one serum, contained anti-Ro, and, of 27 dsDNA 
positive sera, 22 sera also had anti-histone specificity). Although secondary 
to the sample size, the study was not able to statistically comment on an 
association between Sm and U1 RNP, six of ten Sm positive patients had 
both Sm and U1 RNP. Chi-square analysis most strongly correlated anti¬ 
histone and anti-dsDNA antibodies. Anti-histone antibodies also correlated 
with anti-Ul RNP and anti-Ro antibodies. (Given an average number of 
three autoantibodies per patient and that these specificities are the most 
prevalent autoantibody specificities, this association can be explained by 
statistical probability.) Chi-square analysis also correlated anti-Ro with 
anti-La antibodies, a commonly found set. 
The present study defined more clearly the average number of 
autoantibody sets per lupus patient than the studies currently in the 
literature. The current study and 12 identified studies in the literature 
showed an average of greater than one autoantibody set per patient. 
Furthermore, it has been shown that severely ill SLE patients can have 
greater than six autoantibody specificities (Boey et al., 1988). Although this 
study did not examine disease severity, two patients had six autoantibody 
specificities. The greatest number of antibody sets found in a single patient 
was four, which was shown in five patients. 
This study supports some theories of etiology over others. At least 
nine different specificities were demonstrated in this group of SLE patients 
supporting the generally accepted notion that SLE is manifested by a 
polyclonal autoantibody response. Secondly, autoantibodies to epitopes on 
the same macromolecular structure, such as Ro and La, Sm and Ul, and 
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dsDNA and histones, tended to occur in linked sets further supporting that 
macromolecular structures are targeted in the immune response of SLE. 
Other research also supports this concept. It has been shown that histone- 
specific T cells can help anti-dsDNA antibody production. In MRL/lpr mice, 
antibodies specific for native chromatin are detected before DNA and 
histone specificities. Craft et al. have shown in normal mice that once T 
cell tolerance to one snRNP protein is lost, in the presence of spliceosomes, 
the immune response can expand to target other snRNP proteins. (Craft 
1992) 
On an average, approximately two sets were found in each patient. 
These results support a global defect in immune tolerance; therefore, the 
following etiologic theories appear more likely: (1) polyclonal T cell 
activation (2) polyclonal B cell activation (3) suppressor T cell defect (4) Th 
overactivation (5) role of immunological privileged sites (6) activation of 
ignorant cells (7) defect in T cell tolerance or (8) defect in B cell tolerance. 
However, the limited number of autoantibody specificities in the present 
study suggests that an antigen-directed mechanism is also functioning. 
This suggests that the etiologic defect is not simply a pure polyclonal T cell 
activation defect, polyclonal B cell activation defect, defect in T suppressor 
or T helper cells, or defect in T or B cell tolerance. Other evidence 
supporting immunogen-directed B cell autoantibody production is outlined 
by Craft (unpublished), "autoantibodies in lupus are high affinity, high 
titer, and of IgG isotype. In lupus mice, polyclonal B cell activation 
precedes specific ANA production." He suggests that autoantibody 
production may be divided into two steps: polyclonal B cell activation and 
then clonal selection by self antigens. 

58 
The results of this study are not as consistent with the etiologic 
theories which imply that the autoimmune response is due solely to an 
antigenically similar cross-reacting antigen, which include the theories of 
molecular mimicry, cryptic self, and neoself. In order for this data to be 
consistent with the molecular mimicry model, all antigens targeted by an 
individuals sera would at some point need to be a part of the same 
macromolecular structure; more than one molecular mimicry event on 
average must occur; or the inciting antigen must not be protein specific but 
charge specific. 
The present study has limitations. The study sample size of 68 SLE 
patients was not adequate to study the prevalence of anti-ribosome P, 
PCNA, Ku, or Ki antibodies, as well as various clinical manifestations, 
with statistical significance. This study did not correlate autoantibody 
patterns, only specific autoantibodies, with clinical manifestations. 
Furthermore, the utility of studying antibody/clinical manifestations has 
been questioned (Tan 1989; Craft 1992), and it is important to remember that 
normal individuals have been shown to possess low levels of antibodies to 
Ro (15%), La (7.5%), dsDNA, and ssDNA. 
The methods used have limitations. Although the prevalence of anti- 
ribosomal P proteins has been studied with immunoprecipitation in the 
past (Boey et al., 1988), western blotting is a more specific technique (Elkon 
et al., 1988). 35S immunoprecipitation labels only those proteins with 
methionine; therefore, methionine deficient proteins were not adequately 
detected with the 35S immunoprecipitation method (although U1 RNP, Sm 
Ro, and La were also detected using ELISAs which are sensitive regardless 
of methionine content). The utility of Chi-square analysis in the medical 
literature has been questioned (Jekel, personal communication). 
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Finally, disease activity and therapy may influence autoantibody 
levels (Houtman et al., 1985). Forty-three percent of patients in this study 
were on steroids or anti-nuclear therapy when sera were drawn; active 
lupus was not a selection criterion for sera used. Therefore, frequencies in 
this series may not be strictly comparable to other studies in the literature. 
The utility of studying autoantibody profiles in SLE patients is 
multifold. For example, using human autoantibodies, the molecular 
structure of many autoantigens and cellular processes such as pre-mRNA 
splicing and DNA replication have been elucidated. Autoantibody profiles 
have etiologic, diagnostic, and therapeutic utility. The results of this study 
and studies found in the literature support specific etiologic theories. This 
study confirmed that several autoantibody specificities can be used to 
predict particular clinical manifestations. Furthermore, studying 
autoantibodies has also led to many therapeutic strategies. For example, 
extended survival in NZW/NZB mice, a murine model of lupus, by the 
administration of an anti-idiotypic antibody has been demonstrated by 
Hahn and Ebling (reviewed in Christian and Elkon, 1986). 
FURTHER RESEARCH 
At least two specific questions arose during the course of this project. 
First, twenty patients had previously unidentified bands which were 
considered individual specificities. This may be valid given that it is very 
possible that these represent previously unidentified specificities. However, 
it is also possible that these bands represent a degradation product; 
therefore, leading to a slight overestimation of the number of autoantibody 
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sets per patient. (The average number of sets, disregarding these bands, is 
still greater than one.) 
Secondly, sixteen patients had no specificities identified. There are 
several possible explanations: (1) these patients do not have any 
autoantibodies yet have SLE; (2) these patients do not have either 
autoantibodies or SLE; (3) the assays used in this study are not adequate to 
detect the specificities in these sera; or (4) the autoantibodies were degraded 
while in storage. 
These issues represent opportunities of further research and, as 
newer assays are developed, other investigators may want to re-screen 
these sera. More globally, this project serves as a reminder that the etiology 
of SLE is a complex question which has only begun to be answered. 
Nevertheless, all scientific questions must be answered in parts, and much 
light-shedding data has been accumulated. This project suggests that 
further research may best focus on hypotheses that account for a global 
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